Ionis plans to present the complete data of this study at an upcoming scientific conference. Meanwhile, the key Phase 3 CORE and CORE2 research results of olezarsen for the treatment of severe hypertriglyceridemia (sHTG) are expected to be announced in the third quarter of 2025.
Triglycerides are an important form of fat that provides energy to the human body. For adults, the ideal triglyceride level should usually be below 150 mg/dL, and exceeding this value may indicate the presence of hypertriglyceridemia. If the level is above 500 mg/dL, it is considered severe hypertriglyceridemia, which is a common metabolic abnormality. Although there are standard treatments, millions of people still face the potential life threat of acute pancreatitis (AP) and atherosclerotic cardiovascular disease. For sHTG patients with triglyceride levels exceeding 880 mg/dL, especially those with familial chylomicron syndrome (FCS), the risk of developing acute pancreatitis is higher.
Essence is a global, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. The study included 1478 patients aged 18 years and older with moderate hypertriglyceridemia, defined as fasting triglyceride levels ≥ 150 mg/dL to<500 mg/dL and diagnosed or at risk of ASCVD. A small number of participants (9%) had fasting triglycerides ≥ 500 mg/dL at baseline. The study participants received at least four weeks of stable and optimized standard lipid-lowering therapy before screening. Participants were randomly assigned to receive subcutaneous injections of 50 mg (n=276) or 80 mg (n=832) olezarsen or placebo (n=369) every 4 weeks for 12 months.
The primary endpoint was the percentage change in abdominal TG levels relative to baseline at 6 months compared to placebo. The key secondary endpoints include the percentage change in TG levels of patients at 12 months, the proportion of patients achieving fasting TG<150 mg/dL, and the percentage change in other lipid parameters relative to placebo during treatment.
The analysis showed that the trial reached its primary endpoint, and at 6 months, the 80mg and 50mg dose groups achieved a 61% and 58% reduction in TG levels compared to placebo, respectively (p<0.0001). Olezarsen also achieved all key secondary endpoints in the study. The TG levels of the vast majority of participants decreased to<150mg/dL, reaching normal TG levels.
Olezarsen demonstrated good safety and tolerability characteristics in his research. The most common treatment-related adverse events in the Olezarsen group were injection site reactions, which occurred at a higher rate than in the placebo group and were mostly mild.
Olezarsen is an antisense oligonucleotide therapy aimed at inhibiting the body's production of apolipoprotein C-III (apoC-III, a protein produced in the liver that regulates TG metabolism in the blood). The US FDA granted orphan drug status and breakthrough therapy designation (BTD) to this therapy in February 2024, and approved its use as an adjuvant therapy for dietary control to reduce triglycerides in adult patients with familial chylomicron syndrome in December.
<Reprinted from WuXi AppTec>







